GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Net Change in Cash

Antengene (HKSE:06996) Net Change in Cash : HK$-466.11 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Antengene's Net Change in Cash for the six months ended in Jun. 2024 was HK$-209.07 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-466.11 Mil.

Antengene Net Change in Cash Historical Data

The historical data trend for Antengene's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Net Change in Cash Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial 2,137.92 -955.21 -791.09 61.87 -

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -370.12 318.91 -257.04 -209.07 -

Antengene Net Change in Cash Calculation

Antengene's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-728.208+642.121+144.208+3.747
=61.87

Antengene's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-185.134+-27.15+-7.853+11.072
=-209.07

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-466.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Antengene's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Net Change in Cash
Comparable Companies
HKSE:02181 HKSE:02487 HKSE:02563 HKSE:06978 HKSE:02566 HKSE:03681 HKSE:01875 HKSE:02137 HKSE:01521 HKSE:02509 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
722:Germany
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Website
https://www.antengene.com
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Executives
Mei Jay 2201 Interest of corporation controlled by you
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines